Skip to content

Point-of-care Health Literacy and Activation Information to Improve Diabetes Care

Point-of-care Health Literacy and Activation Information to Improve Diabetes Care

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01876485
Acronym
EPIC
Enrollment
280
Registered
2013-06-12
Start date
2015-07-13
Completion date
2018-02-09
Last updated
2019-06-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus

Keywords

Diabetes Mellitus, health literacy, patient activation, goals of care

Brief summary

This hybrid effectiveness/implementation trial will be conducted in two phases over four years. In Phase 1, the investigators will evaluate the process of implementing a collaborative, diabetes goal-setting intervention (Empowering Patients in Chronic Care \[EPIC\]) personalized to self-reported patient activation and functional health literacy (FHL) levels into routine primary care practices. In Phase 2, the investigators will conduct a randomized, clinical trial to compare the effectiveness of EPIC to enhanced usual care (EUC). In Phase 2, the investigators will conduct a randomized clinical trial enrolling 284 Veterans with poorly controlled diabetes defined by average hemoglobin A1c over the last six months of \>= 8% to receive EPIC or enhanced usual care (EUC). Consented subjects will be allocated evenly between EPIC and EUC. EPIC consists of six 1-hour group sessions focusing on 1) Your Health, Your Values, 2) Diabetes ABCs, 3) Setting Goals and Making Action Plans, 4) Communication with Your Health Care Provider, 5) Staying Committed to Your Goals, and 6) Reviewing and Planning for the Future. After each group session, a one-on-one session between a designated PACT member and patient participants will focus on collaborative goal-setting. Patients randomized to EUC will be referred to the PACT RN Care Manager for diabetes management, and will also receive a packet of educational materials regarding diabetes management, including a letter delineating the diabetes management resources available at their facility. Study measurements using self-reported questionnaires and blood tests to assess blood sugar control will be obtained at baseline, post-intervention, and post-six month maintenance period.

Detailed description

Project Background: Diabetes mellitus is a highly prevalent chronic condition, affecting one in four Veterans who use the Veterans Affairs (VA) health care system. Self-management skills are critical for controlling diabetes and reducing its cardiovascular sequela. Providing diabetic patients with effective self-management training and support can be challenging due to time constraints at primary care encounters and limited clinician training with behavior change. The investigators have previously demonstrated that a group-based, VA primary care intervention to help patients set highly effective, evidence-based diabetes goals had a positive impact on both diabetes self-efficacy and hemoglobin (Hb) A1c levels. This study aims to evaluate the process of implementing a collaborative goal-setting intervention personalized to patient activation and health literacy levels (i.e. Empowering Patients in Chronic Care \[EPIC\]) into routine PACT care and to evaluate the effectiveness of this intervention relative to usual care. Project Objectives: Specific Aim 1: Assess effective processes for and costs associated with implementing a collaborative diabetes goal-setting intervention personalized to patient activation and FHL (i.e., EPIC) into the routine workflows of PACTs. H1: Formative measures within the PARIHS framework (evidence, context, facilitation) will be associated with implementation of EPIC (defined by reach, adoption, cost effectiveness, and fidelity measures) into routine PACT care. Specific Aim 2: Evaluate the effectiveness of delivering collaborative goal-setting personalized to patient activation and FHL on clinical (HbA1c) and patient-centered (Diabetes Distress Scale) outcomes among eligible patients in enrolled PACTs. H2: Patients receiving collaborative goal-setting personalized to activation and FHL levels will have significant improvements in a) HbA1c and b) Diabetes Distress Scale levels, respectively, at post-intervention compared with patients receiving enhanced usual care. H3: Patients receiving collaborative goal-setting personalized to activation and FHL levels will maintain significant improvements in a) HbA1c and b) Diabetes Distress Scale levels at post-maintenance follow-up, respectively, compared with patients receiving enhanced usual care. Project Methods: In Phase 1 of the study, the investigators will implement EPIC into routine PACT care. The investigators will conduct a mixed-methods formative evaluation that includes 33-48 key informant interviews with VA leadership, clinicians, and staff and an assessment of organizational readiness for change. This evaluation will identify how group and one-on-one sessions of EPIC can best be implemented into routine workflows of PACT. In Phase 2, the investigators will conduct a randomized clinical trial enrolling 284 patients with poorly controlled diabetes defined by average hemoglobin A1c of 8% to receive EPIC or enhanced usual care. The patient will serve as the unit of randomization. EPIC consists of six 1-hour group sessions focusing on 1) Your Health, Your Values, 2) Diabetes ABCs, 3) Setting Goals and Making Action Plans, 4) Communication with Your Health Care Provider, 5) Staying Committed to Your Goals, and 6) Reviewing and Planning for the Future. After each group session, a one-on-one session between a designated PACT member and patient participants will focus on collaborative goal-setting. Designated PACT members will be trained to personalize goal-setting using patient-reported activation and health literacy data. The investigators will collect laboratory and survey data at baseline, post-intervention, and post-maintenance phase. The investigators will evaluate the effectiveness of personalized goal-setting compared to enhanced usual care on clinical (e.g., hemoglobin A1c) and patient-centered (e.g., Diabetes Distress Scale) outcomes.

Interventions

BEHAVIORALEmpowering Patients in Chronic Care (EPIC)

EPIC group training sessions consisting of 6 one-hour group sessions occurring over a 6-month period. Group sessions will consist of behavioral coaching focused on diabetes management. Following each group-session, patients enrolled in the intervention arm will meet with a designated member of their primary care team to personalize diabetes goals and action plans.

BEHAVIORALEnhanced Usual Care (EUC)

Patients randomized to EUC will be referred to the PACT RN Care Manager for diabetes management, and will also receive a packet of educational materials regarding diabetes management, including a letter delineating the diabetes management resources available at their facility.

Sponsors

VA Office of Research and Development
Lead SponsorFED

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Veterans receiving primary care at VA study sites who are enrolled in the panels of participating primary care teams * Veterans with ICD-9-CM and/or ICD-10 codes indicating a diagnosis of diabetes * Veterans with an average HbA1c level \> 8% in the prior 6 months

Exclusion criteria

The investigators will exclude Veterans with the following clinical conditions that would render participation in a group clinic inappropriate: * metastatic cancer or receiving hospice care * limited life expectancy * clinician recommendations to not titrate therapy due to prior history of significant hypoglycemic events * age \<18 years * active bipolar or psychotic disorder The investigators will also exclude Veterans, who at the time of screening: * cannot attend monthly group clinic sessions due to transportation or availability barriers * have significant cognitive impairment * have active substance-abuse disorders * are not comfortable discussing their health and health care in a peer-group setting Patients will be secondarily excluded if their HbA1C level falls below 7.5% at baseline.

Design outcomes

Primary

MeasureTime frameDescription
Changes in Percent Glycosylated Hemoglobin (HbA1c) Levels During InterventionHbA1c levels will be measured at baseline, four months, and ten months.Measures of HbA1c will be taken to assess average blood glucose levels throughout the study as an indicator of diabetes control.
Change in Diabetes Specific Quality of LifeDiabetes specific quality of life will be measured at baseline, four months, and ten months.The Diabetes Distress Scale (DDS) will be used to assess diabetes quality of life throughout the study. Minimum value: 1; Maximum value: 6. Higher scores indicate a higher level of diabetes distress.

Countries

United States

Participant flow

Participants by arm

ArmCount
Arm 1: Empowering Patients in Chronic Care (EPIC)
Patients in the intervention arm will receive the Empowering Patients in Chronic Care group training sessions consisting of 6 one-hour group sessions occurring over a 6-month period. Group sessions will consist of behavioral coaching focused on diabetes management. Following each group-session, patients enrolled in the intervention arm will meet with a designated member of their primary care team to personalize diabetes goals and action plans. Empowering Patients in Chronic Care (EPIC): EPIC group training sessions consisting of 6 one-hour group sessions occurring over a 6-month period. Group sessions will consist of behavioral coaching focused on diabetes management. Following each group-session, patients enrolled in the intervention arm will meet with a designated member of their primary care team to personalize diabetes goals and action plans.
140
Arm 2: Enhanced Usual Care (EUC)
The Enhanced Usual Care (EUC) arm will serve as a concurrent control group to compare to the intervention arm of the study. Patients randomized to EUC will be referred to the PACT RN Care Manager for diabetes management, and will also receive a packet of educational materials regarding diabetes management, including a letter delineating the diabetes management resources available at their facility. Enhanced Usual Care (EUC): Patients randomized to EUC will be referred to the PACT RN Care Manager for diabetes management, and will also receive a packet of educational materials regarding diabetes management, including a letter delineating the diabetes management resources available at their facility.
140
Total280

Baseline characteristics

CharacteristicArm 1: Empowering Patients in Chronic Care (EPIC)Arm 2: Enhanced Usual Care (EUC)Total
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
94 Participants91 Participants185 Participants
Age, Categorical
Between 18 and 65 years
46 Participants49 Participants95 Participants
Age, Continuous67.39 Years
STANDARD_DEVIATION 8.57
66.94 Years
STANDARD_DEVIATION 8.34
67.17 Years
STANDARD_DEVIATION 8.44
Diabetes Distress Scale (DDS)2.41 Units on a scale
STANDARD_DEVIATION 1.05
2.45 Units on a scale
STANDARD_DEVIATION 1.02
2.43 Units on a scale
STANDARD_DEVIATION 1.03
Ethnicity (NIH/OMB)
Hispanic or Latino
22 Participants11 Participants33 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
116 Participants125 Participants241 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
2 Participants4 Participants6 Participants
Percent Glycosylated Hemoglobin (HbA1c)9.11 Percent/DCCT
STANDARD_DEVIATION 1.6
9.06 Percent/DCCT
STANDARD_DEVIATION 1.32
9.08 Percent/DCCT
STANDARD_DEVIATION 1.46
Region of Enrollment
United States
140 Participants140 Participants280 Participants
Sex: Female, Male
Female
9 Participants7 Participants16 Participants
Sex: Female, Male
Male
131 Participants133 Participants264 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 1404 / 140
other
Total, other adverse events
0 / 1400 / 140
serious
Total, serious adverse events
0 / 1400 / 140

Outcome results

Primary

Change in Diabetes Specific Quality of Life

The Diabetes Distress Scale (DDS) will be used to assess diabetes quality of life throughout the study. Minimum value: 1; Maximum value: 6. Higher scores indicate a higher level of diabetes distress.

Time frame: Diabetes specific quality of life will be measured at baseline, four months, and ten months.

Population: Seven participants did not complete the DDS at baseline. Therefore, sample sizes for DDS are lower than for HbA1c.~Although not all of the 138/135 per group with DDS at baseline completed each the post-intervention and maintenance assessments, intent to treat analyses were conducted which enabled us to use the full number across time points.

ArmMeasureGroupValue (MEAN)Dispersion
Arm 1: Empowering Patients in Chronic Care (EPIC)Change in Diabetes Specific Quality of LifeBaseline2.41 Units On A ScaleStandard Deviation 1.05
Arm 1: Empowering Patients in Chronic Care (EPIC)Change in Diabetes Specific Quality of Life10 Months1.96 Units On A ScaleStandard Deviation 0.76
Arm 1: Empowering Patients in Chronic Care (EPIC)Change in Diabetes Specific Quality of Life4 Months2.02 Units On A ScaleStandard Deviation 0.81
Arm 2: Enhanced Usual Care (EUC)Change in Diabetes Specific Quality of LifeBaseline2.45 Units On A ScaleStandard Deviation 1.02
Arm 2: Enhanced Usual Care (EUC)Change in Diabetes Specific Quality of Life10 Months2.27 Units On A ScaleStandard Deviation 1.05
Arm 2: Enhanced Usual Care (EUC)Change in Diabetes Specific Quality of Life4 Months2.30 Units On A ScaleStandard Deviation 0.99
Comparison: We compared group differences in DDS at 4 months. The value of DDS at 4 months was the dependent variable, treatment group was the independent variable, and baseline DDS was a covariate. Power calculations were based on effect sizes for the DDS in similar trial that revealed small-to-medium effect sizes. Our goal was to include 130 patients in each arm. The randomized samples (n=138 EPIC, n=135 EUC) exceed the required 130 per group.p-value: 0.003proc mixed in SAS (multilevel modeling)
Comparison: We compared group differences in DDS at 10 months. The value of DDS at 10 months was the dependent variable, treatment group was the independent variable, and baseline DDS was a covariate. Power calculations were based on effect sizes for the DDS in similar trial that revealed small-to-medium effect sizes. Our goal was to include 130 patients in each arm. The randomized samples (n=138 EPIC, n=135 EUC) exceed the required 130 per group.p-value: 0.003proc mixed in SAS (multilevel modeling)
Primary

Changes in Percent Glycosylated Hemoglobin (HbA1c) Levels During Intervention

Measures of HbA1c will be taken to assess average blood glucose levels throughout the study as an indicator of diabetes control.

Time frame: HbA1c levels will be measured at baseline, four months, and ten months.

Population: Although not all of the 140 per group with HbA1c at baseline completed each the post-intervention and maintenance assessments, intent to treat analyses were conducted which enabled us to use the full 140 across time points.

ArmMeasureGroupValue (MEAN)Dispersion
Arm 1: Empowering Patients in Chronic Care (EPIC)Changes in Percent Glycosylated Hemoglobin (HbA1c) Levels During Intervention10 Months8.68 Percentage/DCCTStandard Deviation 1.53
Arm 1: Empowering Patients in Chronic Care (EPIC)Changes in Percent Glycosylated Hemoglobin (HbA1c) Levels During InterventionBaseline9.11 Percentage/DCCTStandard Deviation 1.6
Arm 1: Empowering Patients in Chronic Care (EPIC)Changes in Percent Glycosylated Hemoglobin (HbA1c) Levels During Intervention4 Months8.61 Percentage/DCCTStandard Deviation 1.27
Arm 2: Enhanced Usual Care (EUC)Changes in Percent Glycosylated Hemoglobin (HbA1c) Levels During Intervention4 Months9.04 Percentage/DCCTStandard Deviation 1.7
Arm 2: Enhanced Usual Care (EUC)Changes in Percent Glycosylated Hemoglobin (HbA1c) Levels During Intervention10 Months8.79 Percentage/DCCTStandard Deviation 1.55
Arm 2: Enhanced Usual Care (EUC)Changes in Percent Glycosylated Hemoglobin (HbA1c) Levels During InterventionBaseline9.06 Percentage/DCCTStandard Deviation 1.32
Comparison: We compared group differences in HbA1c at 4. The value of HbA1c at 4 months was the dependent variable, treatment group was the independent variable, and baseline HbA1c was a covariate.~Power calculations were based on effect sizes for the HbA1c in similar trial that revealed small-to-medium effect sizes. Our goal was to include 130 patients in each arm. The randomized samples (n = 140 EPIC, n = 140 EUC) exceed the required 130 per group.p-value: 0.003proc mixed in SAS (multilevel modeling)
Comparison: We compared group differences in HbA1c at 10 months. The value of HbA1c at 10 months was the dependent variable, treatment group was the independent variable, and baseline HbA1c was a covariate.~Power calculations were based on effect sizes for the HbA1c in similar trial that revealed small-to-medium effect sizes. Our goal was to include 130 patients in each arm. The randomized samples (n = 140 EPIC, n = 140 EUC) exceed the required 130 per group.p-value: 0.6proc mixed in SAS (multilevel modeling)

Source: ClinicalTrials.gov · Data processed: Feb 12, 2026